MSC-Derived Extracellular Vesicles May Reprogram the Inflamed Spinal Cord After Injury — But the Road to the Clinic Is Steep

When a spinal cord is crushed or severed, the damage does not end with the mechanical blow. In the minutes that follow, a secondary catastrophe begins: the blood-spinal cord barrier breaks down, edema swells the tissue, oxidative stress and complement activation spread, and a storm of inflammatory cytokines such as TNF-α and IL-1β floods the lesion. This prolonged secondary cascade, evolving over hours, days, and weeks, is now considered the most realistic therapeutic target after spinal cord injury — and a sweeping new review published in Frontiers in Cellular Neuroscience argues that tiny vesicles shed by mesenchymal stem/stromal cells (MSCs) may be uniquely suited to reprogram it.

The review, led by Hang Yu and colleagues at Qilu Hospital of Shandong University and Tianjin Medical University General Hospital, synthesizes preclinical evidence on MSC-derived extracellular vesicles, abbreviated MSC-EVs. These lipid-bilayer nanoparticles, typically 30 to 150 nanometers in diameter with densities of roughly 1.13–1.19 g/mL, are released by MSCs and carry a dense molecular payload: microRNAs, messenger RNA fragments, long non-coding RNAs, circular RNAs, tRNA-derived fragments, proteins, and lipids. Because they lack nuclei and cannot proliferate, MSC-EVs may sidestep some of the risks that have haunted live-cell transplantation — ectopic engraftment, uncontrolled division, microvascular obstruction, and batch-to-batch variability in cell survival.

But the review is refreshingly blunt about terminology. Following the Minimal Information for Studies of Extracellular Vesicles (MISEV) recommendations, the authors refuse to call every vesicle an exosome. Strictly speaking, exosomes are vesicles born through the endosomal pathway and released when multivesicular bodies fuse with the plasma membrane. Most spinal cord injury studies isolate vesicles by ultracentrifugation, precipitation, size-exclusion chromatography, or commercial kits and characterize them by size, morphology, and markers such as CD9, CD63, CD81, TSG101, Alix, and Hsp70 — criteria that identify small extracellular vesicles or exosome-like vesicles but rarely prove endosomal origin. The umbrella term MSC-EV, the authors insist, is essential for manufacturing, potency testing, regulatory classification, and honest cross-study comparison.

So what do MSC-EVs actually do in the injured cord? The review organizes the evidence around the inflammatory microenvironment as the primary target. Preclinical studies show that MSC-EVs suppress complement activation — a humoral inflammatory arm long implicated in secondary degeneration — and inhibit the NLRP3 inflammasome, the molecular machine that cleaves pro-IL-1β into its active form. Epidural fat MSC-derived vesicles, anatomically relevant to the spinal environment, attenuated NLRP3, ASC, cleaved caspase-1, and IL-1β expression in rat contusion models. Bone marrow MSC-EVs reduced A1-like neurotoxic reactive astrocyte markers, including complement C3, through downregulation of phosphorylated NF-κB p65, and improved blood-spinal cord barrier integrity by preserving tight-junction proteins ZO-1, occludin, and claudin-5. Reduced Evans blue leakage in treated animals confirmed that the vascular wall had genuinely tightened, not merely changed its marker profile.

The authors are equally careful with the M1/M2 macrophage dichotomy and the A1/A2 astrocyte framework. Both binary classifications, they argue, are convenient experimental readouts — iNOS, CD86, Arg1, CD206, TNF-α, IL-1β, IL-10 — rather than definitive cell identities. Single-cell and spatial transcriptomics increasingly reveal that microglia, infiltrating macrophages, and reactive astrocytes adopt diverse, context-dependent states that shift over time and across lesion compartments. Future studies, the review urges, should use flow cytometry, single-cell transcriptomics, spatial transcriptomics, and proteomics to define how MSC-EVs reshape these heterogeneous populations rather than forcing them into two boxes.

Mechanistically, the review maps a dense signaling web. MSC-EVs regulate NF-κB, PI3K/Akt, ERK, RhoA/ROCK, PTEN/PI3K/Akt, and Wnt/β-catenin pathways, and deliver regulatory microRNAs including miR-133b, miR-21, miR-29, miR-126, and miR-486-5p. miR-133b inhibits RhoA/ROCK signaling to relieve cytoskeletal inhibition and support axonal plasticity, while also engaging ERK/CREB, STAT3, and PI3K/Akt/mTOR. miR-21 targets PTEN to activate PI3K/Akt and modulates FasL, PDCD4, and NF-κB-related pathways — though it is context-dependent and may participate in fibrotic remodeling in some settings. miR-29b regulates extracellular matrix and fibro-inflammatory remodeling; miR-126 promotes angiogenesis and neurogenesis; and miR-486-5p has been reported to alleviate injury through the PTEN/PI3K/Akt axis, an emerging mechanism that still requires independent replication and loss-of-function validation.

Crucially, the review insists that a single cargo or pathway cannot explain therapeutic activity across all stages of injury. In the acute phase, within hours to days, priorities are suppressing destructive inflammation, stabilizing the blood-spinal cord barrier, reducing edema, limiting complement activation, and inhibiting inflammasome signaling — effects linked to NF-κB, NLRP3, PI3K/Akt-mediated survival, and endothelial barrier integrity. In the subacute phase, spanning days to weeks, inflammation remains active but repair processes dominate: astrocyte reactivity, microglial heterogeneity, angiogenesis, oligodendrocyte survival, axonal sprouting, and matrix remodeling. miR-133b may be more relevant here because of its RhoA/ROCK association, while miR-126 supports neurovascular repair and miR-29 begins to influence matrix deposition. In the chronic phase, evidence is markedly thinner; proposed actions on scar maturation, durable remyelination, and long-range circuit reconstruction should be treated as priority directions rather than established effects.

The evidence base itself is uneven, the authors warn. Some mechanisms are supported by gain- and loss-of-function experiments — miRNA-modified MSCs, miRNA-deficient vesicles, pathway inhibitors, target-gene validation — whereas others rest mainly on marker expression changes after vesicle administration and should be interpreted as associative rather than causal. Many animal studies use small sample sizes, single-dose regimens, short follow-up periods, and male rodents only, raising serious publication bias concerns. Functional improvement in open-field locomotor scores can be influenced by spontaneous recovery, injury severity variability, animal handling, and observer blinding. The review calls for prespecified primary outcomes, adequate sample-size calculations, randomized allocation, blinded assessment, both sexes where appropriate, dose–response testing, biodistribution analysis, and predefined criteria for adverse effects.

Donor and source heterogeneity add another layer of complexity. Vesicles from bone marrow, adipose, umbilical cord, dental pulp, and epidural fat MSCs differ in RNA cargo, protein composition, lipid content, immunomodulatory potency, angiogenic activity, and biodistribution. Bone marrow MSC-EVs are the most frequently studied and have been linked to complement inhibition, A1-like astrocyte suppression, autophagy activation, and barrier repair. Umbilical cord MSC-EVs are attractive for scalable manufacturing and may possess strong immunomodulatory and pro-angiogenic properties. Adipose-derived MSC-EVs are abundant and accessible, but donor metabolic state can alter cargo and function — studies showing impaired protective effects of vesicles from obese MSCs, with miR-21 deficiency associated with reduced therapeutic activity, illustrate this vividly. Direct head-to-head comparisons under identical conditions remain rare, so claims about superiority of one source over another are premature.

Delivery, storage, and regulatory hurdles complete the translational gauntlet. Intravenously administered vesicles are frequently taken up by the liver, spleen, lung, and the mononuclear phagocyte system, leaving only a fraction to reach the injured cord; inflammation-associated lesion enrichment should be described as partial enrichment rather than precise targeting. Surface modification, biomaterial-assisted local delivery, intrathecal administration, and engineered targeting strategies may improve lesion exposure, but require rigorous biodistribution and safety validation. Electroactive hydrogels loaded with human umbilical cord MSC-EVs have been reported to remodel lesion microenvironments and support neural circuit reconstruction, suggesting that local delivery and biomaterial-based strategies may enhance vesicle retention. Storage stability is affected by temperature, freeze–thaw cycles, formulation, and processing; trehalose and other stabilizers may reduce aggregation and cryodamage, while freeze-drying may improve pharmaceutical feasibility — but stability should be assessed by functional potency assays linked to anti-inflammatory activity, barrier repair, neuroprotection, and glial modulation, not merely by particle concentration or size distribution.

No MSC-EV product has been formally approved by major regulatory agencies for spinal cord injury treatment, and clinical efficacy remains unproven. Translation will require good manufacturing practice-compliant production, validated identity and purity assays, sterility and endotoxin testing, stability assessment, biodistribution analysis, and mechanism-linked potency assays. The review concludes that MSC-EVs are more likely to be developed as an adjunctive therapy rather than a stand-alone intervention, combined with biomaterial-assisted local delivery, rehabilitation to shape activity-dependent plasticity, and neuromodulation to promote circuit engagement. Only after standardized nomenclature, source-specific comparisons, both-sex animal experiments, chronic-stage models, large-animal validation, and potency assays linked to immunomodulatory and barrier-protective functions are addressed can MSC-EVs credibly advance from experimental microenvironment modulators to candidate therapeutics for human spinal cord injury.

Subject of Research: Neuroscience

Article Title: MSC-derived extracellular vesicles for spinal cord injury: inflammatory microenvironment modulation, stage-dependent repair mechanisms, and translational challenges

Article References: Yu, H., Liu, Y., Yin, S., Hu, H., Li, L., Zhu, T., Liu, J., Liu, S., Zhao, C., & Feng, S. (2026). MSC-derived extracellular vesicles for spinal cord injury: inflammatory microenvironment modulation, stage-dependent repair mechanisms, and translational challenges. Frontiers in Cellular Neuroscience, 20, Article 1960271. https://doi.org/10.3389/fncel.2026.1960271

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1960271

Keywords: extracellular vesicles, mesenchymal stem cells, spinal cord injury, neuroinflammation, microRNA, blood-spinal cord barrier, astrocytes, translational medicine, MSC-derived, extracellular, vesicles, spinal